Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results

Amylyx Pharmaceuticals (NASDAQ:AMLX) posted its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01, FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Enrollment for the pivotal LUCIDITY Phase 3 trial is complete, the open‑label extension is underway, and management expects top‑line results in Q3 2026.
• Amylyx ended Q4 with $317 million in cash and marketable securities, which management says provides a cash runway into 2028 to fund key milestones including the LUCIDITY readout and potential launch activities.
• The company is actively preparing an NDA and building commercial and medical infrastructure now to support a potential 2027 commercialization of avexitide if approved, including market research, KOL engagement, and payer strategy work.
• Pipeline progress: Amylyx nominated AMX0318 (a long‑acting GLP‑1 receptor antagonist) as a development candidate with IND‑enabling work underway targeting an IND in 2027, and AMX0114 advanced in the Phase 1 ALS LUMINA trial with cohort enrollment ongoing.
• Management modeled conservative powering assumptions for LUCIDITY (including up to a 50% placebo effect and 35% effect vs placebo) despite prior trials showing low placebo response, underscoring trial outcome uncertainty and regulatory risk.

Amylyx Pharmaceuticals Trading Down 7.8%

Shares of NASDAQ AMLX opened at $14.11 on Wednesday. The firm has a fifty day simple moving average of $13.82 and a two-hundred day simple moving average of $13.15. The firm has a market capitalization of $1.55 billion, a PE ratio of -7.84 and a beta of -0.31. Amylyx Pharmaceuticals has a 12 month low of $2.60 and a 12 month high of $17.49.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AMLX. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $21.00 target price for the company. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Bank of America raised their target price on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Finally, HC Wainwright increased their price target on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.89.

Insider Activity at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 1,995 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the sale, the chief executive officer directly owned 3,379,398 shares in the company, valued at $46,939,838.22. The trade was a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 136,193 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the sale, the chief executive officer directly owned 3,378,621 shares in the company, valued at approximately $45,915,459.39. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 151,203 shares of company stock valued at $2,028,385 in the last three months. Corporate insiders own 12.30% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Amylyx Pharmaceuticals during the second quarter worth about $243,000. California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $28,000. Ameriprise Financial Inc. lifted its holdings in shares of Amylyx Pharmaceuticals by 643.6% during the second quarter. Ameriprise Financial Inc. now owns 95,219 shares of the company’s stock valued at $610,000 after purchasing an additional 82,414 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after purchasing an additional 3,102,395 shares in the last quarter. Finally, Fred Alger Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the 3rd quarter worth approximately $2,229,000. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.